{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,8]],"date-time":"2026-10-08T01:50:43Z","timestamp":1791424243835,"version":"4.3.3"},"reference-count":77,"publisher":"Elsevier BV","issue":"10","license":[{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,8,14]],"date-time":"2026-08-14T00:00:00Z","timestamp":1786665600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100000865","name":"Gates Foundation","doi-asserted-by":"publisher","award":["INV-088153"],"award-info":[{"award-number":["INV-088153"]}],"id":[{"id":"10.13039\/100000865","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100006492","name":"National Institute of Allergy and Infectious Diseases Division of Intramural Research","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100006492","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000060","name":"National Institute of Allergy and Infectious Diseases","doi-asserted-by":"publisher","award":["1R01AI192628-01"],"award-info":[{"award-number":["1R01AI192628-01"]}],"id":[{"id":"10.13039\/100000060","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["cell.com","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Trends in Parasitology"],"published-print":{"date-parts":[[2026,10]]},"DOI":"10.1016\/j.pt.2026.08.002","type":"journal-article","created":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T03:29:58Z","timestamp":1788233398000},"page":"970-979","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Equitable access to monoclonal antibodies targeting parasites"],"prefix":"10.1016","volume":"42","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-2639-2909","authenticated-orcid":false,"given":"Sahal","family":"Thahir","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4260-8009","authenticated-orcid":false,"given":"Natalie M.","family":"Bowman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5629-0412","authenticated-orcid":false,"given":"Peter D.","family":"Crompton","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3133-0849","authenticated-orcid":false,"given":"Robert A.","family":"Seder","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6877-0093","authenticated-orcid":false,"given":"Kassoum","family":"Kayentao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5167-8079","authenticated-orcid":false,"given":"Tuan M.","family":"Tran","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.pt.2026.08.002_bb0005","doi-asserted-by":"crossref","DOI":"10.1080\/19420862.2019.1703531","article-title":"Antibodies to watch in 2020","volume":"12","author":"Kaplon","year":"2020","journal-title":"MAbs"},{"key":"10.1016\/j.pt.2026.08.002_bb0010","doi-asserted-by":"crossref","DOI":"10.1080\/19420862.2026.2614669","article-title":"Antibodies to watch in 2026","volume":"18","author":"Crescioli","year":"2026","journal-title":"MAbs"},{"key":"10.1016\/j.pt.2026.08.002_bb0015","series-title":"Access to monoclonal antibodies in Africa: a call to action","author":"IAVI and Impact Global Health","year":"2024"},{"key":"10.1016\/j.pt.2026.08.002_bb0020","first-page":"203","article-title":"Clinical and regulatory challenges and opportunities for monoclonal antibodies in low- and middle-income countries: lessons from COVID-19 and beyond","volume":"37","author":"Gieber","year":"2023","journal-title":"Pharmaceut. Med."},{"key":"10.1016\/j.pt.2026.08.002_bb0025","doi-asserted-by":"crossref","first-page":"284","DOI":"10.1016\/S1473-3099(25)00562-6","article-title":"Global, regional, and national burden of Chagas disease, 1990-2023: a systematic analysis for the Global Burden of Disease Study 2023","volume":"26","author":"Disease","year":"2026","journal-title":"Lancet Infect. Dis."},{"key":"10.1016\/j.pt.2026.08.002_bb0030","first-page":"229","article-title":"Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"74","author":"Bray","year":"2024","journal-title":"CA Cancer J. Clin."},{"key":"10.1016\/j.pt.2026.08.002_bb0035","article-title":"Global, regional, and national incidence of six major immune-mediated inflammatory diseases: findings from the global burden of disease study 2019","volume":"64","author":"Collaborators","year":"2023","journal-title":"EClinicalMedicine"},{"key":"10.1016\/j.pt.2026.08.002_bb0040","doi-asserted-by":"crossref","first-page":"2519","DOI":"10.1056\/NEJMoa1515257","article-title":"Seven-year efficacy of RTS,S\/AS01 malaria vaccine among young African children","volume":"374","author":"Olotu","year":"2016","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.pt.2026.08.002_bb0045","doi-asserted-by":"crossref","DOI":"10.1172\/JCI207559","article-title":"Pharmacokinetics and pharmacodynamics of a long-acting monoclonal antibody against malaria in African adults","volume":"136","author":"Tran","year":"2026","journal-title":"J. Clin. Invest."},{"key":"10.1016\/j.pt.2026.08.002_bb0050","doi-asserted-by":"crossref","first-page":"1099","DOI":"10.1038\/s41467-024-45027-2","article-title":"Predicting the risk and speed of drug resistance emerging in soil-transmitted helminths during preventive chemotherapy","volume":"15","author":"Coffeng","year":"2024","journal-title":"Nat. Commun."},{"key":"10.1016\/j.pt.2026.08.002_bb0055","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1186\/s13099-026-00815-7","article-title":"The dual role of intestinal parasites in shaping human gut microbiota: distinguishing helminthic and protozoan dynamics","volume":"18","author":"Sidi Omar","year":"2026","journal-title":"Gut Pathog."},{"key":"10.1016\/j.pt.2026.08.002_bb0060","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pgph.0003418","article-title":"Novel approaches to enable equitable access to monoclonal antibodies in low- and middle-income countries","volume":"4","author":"Malhotra","year":"2024","journal-title":"PLoS Glob. Public Health"},{"key":"10.1016\/j.pt.2026.08.002_bb0065","article-title":"Monoclonal antibodies and Fc-fusion protein biologic medicines: a multinational cross-sectional investigation of accessibility and affordability in Asia Pacific regions between 2010, and 2020","volume":"26","author":"Tong","year":"2022","journal-title":"Lancet Reg. Health West. Pac."},{"key":"10.1016\/j.pt.2026.08.002_bb0070","doi-asserted-by":"crossref","first-page":"576","DOI":"10.1002\/psp4.12224","article-title":"Pharmacokinetics of monoclonal antibodies","volume":"6","author":"Ryman","year":"2017","journal-title":"CPT Pharmacometrics Syst. Pharmacol."},{"key":"10.1016\/j.pt.2026.08.002_bb0075","doi-asserted-by":"crossref","first-page":"1475","DOI":"10.1016\/S0020-7519(00)00119-3","article-title":"Trypanosoma cruzi: skin-penetration kinetics of vector-derived metacyclic trypomastigotes","volume":"30","author":"Schuster","year":"2000","journal-title":"Int. J. Parasitol."},{"key":"10.1016\/j.pt.2026.08.002_bb0080","doi-asserted-by":"crossref","first-page":"689","DOI":"10.1111\/tmi.13915","article-title":"Oral transmission of Chagas disease from a One Health approach: a systematic review","volume":"28","author":"Lopez-garcia","year":"2023","journal-title":"Trop. Med. Int. Health"},{"key":"10.1016\/j.pt.2026.08.002_bb0085","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pntd.0001965","article-title":"Immunosuppression and Chagas disease: a management challenge","volume":"7","author":"Pinazo","year":"2013","journal-title":"PLoS Negl. Trop. Dis."},{"key":"10.1016\/j.pt.2026.08.002_bb0090","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.adk7832","article-title":"Deep humoral profiling coupled to interpretable machine learning unveils diagnostic markers and pathophysiology of schistosomiasis","volume":"16","author":"Saha","year":"2024","journal-title":"Sci. Transl. Med."},{"key":"10.1016\/j.pt.2026.08.002_bb0095","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1111\/j.1469-0691.2006.01362.x","article-title":"Immunoprophylactic evaluation of a 37-kDa Brugia malayi recombinant antigen in lymphatic filariasis","volume":"12","author":"Dabir","year":"2006","journal-title":"Clin. Microbiol. Infect."},{"key":"10.1016\/j.pt.2026.08.002_bb0100","doi-asserted-by":"crossref","first-page":"382","DOI":"10.1111\/j.1365-2249.2006.03081.x","article-title":"Human antibody responses of patients living in endemic areas for schistosomiasis to the tegumental protein Sm29 identified through genomic studies","volume":"144","author":"Cardoso","year":"2006","journal-title":"Clin. Exp. Immunol."},{"key":"10.1016\/j.pt.2026.08.002_bb0105","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pntd.0003049","article-title":"CD16 expression on monocytes in healthy individuals but not schistosome-infected patients is positively associated with levels of parasite-specific IgG and IgG1","volume":"8","author":"Appleby","year":"2014","journal-title":"PLoS Negl. Trop. Dis."},{"key":"10.1016\/j.pt.2026.08.002_bb0110","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1038\/nrmicro2145","article-title":"Common strategies for antigenic variation by bacterial, fungal and protozoan pathogens","volume":"7","author":"Deitsch","year":"2009","journal-title":"Nat. Rev. Microbiol."},{"key":"10.1016\/j.pt.2026.08.002_bb0115","doi-asserted-by":"crossref","DOI":"10.1128\/microbiolspec.AID-0018-2014","article-title":"Efficient methods to isolate human monoclonal antibodies from memory B cells and plasma cells","volume":"2","author":"Corti","year":"2014","journal-title":"Microbiol. Spectr."},{"key":"10.1016\/j.pt.2026.08.002_bb0120","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1038\/s41586-024-08220-3","article-title":"Broadly inhibitory antibodies to severe malaria virulence proteins","volume":"636","author":"Reyes","year":"2024","journal-title":"Nature"},{"key":"10.1016\/j.pt.2026.08.002_bb0125","doi-asserted-by":"crossref","first-page":"502","DOI":"10.1038\/nature12216","article-title":"Severe malaria is associated with parasite binding to endothelial protein C receptor","volume":"498","author":"Turner","year":"2013","journal-title":"Nature"},{"key":"10.1016\/j.pt.2026.08.002_bb0130","doi-asserted-by":"crossref","first-page":"748","DOI":"10.1038\/s41467-024-44962-4","article-title":"Revisiting the Plasmodium sporozoite inoculum and elucidating the efficiency with which malaria parasites progress through the mosquito","volume":"15","author":"Kanatani","year":"2024","journal-title":"Nat. Commun."},{"key":"10.1016\/j.pt.2026.08.002_bb0135","article-title":"Estimation of the total parasite biomass in acute falciparum malaria from plasma PfHRP2","volume":"2","author":"Dondorp","year":"2005","journal-title":"PLoS Med."},{"key":"10.1016\/j.pt.2026.08.002_bb0140","doi-asserted-by":"crossref","first-page":"1530","DOI":"10.1038\/s41590-024-01938-2","article-title":"Monoclonal antibodies to the circumsporozoite proteins as an emerging tool for malaria prevention","volume":"25","author":"Wang","year":"2024","journal-title":"Nat. Immunol."},{"key":"10.1016\/j.pt.2026.08.002_bb0145","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1038\/nbt.1601","article-title":"Enhanced antibody half-life improves in vivo activity","volume":"28","author":"Zalevsky","year":"2010","journal-title":"Nat. Biotechnol."},{"key":"10.1016\/j.pt.2026.08.002_bb0150","doi-asserted-by":"crossref","first-page":"1621","DOI":"10.1056\/NEJMra2312718","article-title":"Neonatal Fc receptor \u2013 biology and therapeutics","volume":"392","author":"Bussel","year":"2025","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.pt.2026.08.002_bb0155","doi-asserted-by":"crossref","first-page":"408","DOI":"10.1038\/nm.4512","article-title":"A human monoclonal antibody prevents malaria infection by targeting a new site of vulnerability on the parasite","volume":"24","author":"Kisalu","year":"2018","journal-title":"Nat. Med."},{"key":"10.1016\/j.pt.2026.08.002_bb0160","doi-asserted-by":"crossref","first-page":"803","DOI":"10.1056\/NEJMoa2034031","article-title":"A monoclonal antibody for malaria prevention","volume":"385","author":"Gaudinski","year":"2021","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.pt.2026.08.002_bb0165","doi-asserted-by":"crossref","DOI":"10.1172\/jci.insight.143958","article-title":"Enhancing durability of CIS43 monoclonal antibody by Fc mutation or AAV delivery for malaria prevention","volume":"6","author":"Kisalu","year":"2021","journal-title":"JCI Insight"},{"key":"10.1016\/j.pt.2026.08.002_bb0170","doi-asserted-by":"crossref","first-page":"1833","DOI":"10.1056\/NEJMoa2206966","article-title":"Safety and efficacy of a monoclonal antibody against malaria in Mali","volume":"387","author":"Kayentao","year":"2022","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.pt.2026.08.002_bb0175","doi-asserted-by":"crossref","first-page":"2682","DOI":"10.1038\/s41591-025-03739-y","article-title":"Anti-sporozoite monoclonal antibody for malaria prevention: secondary efficacy outcome of a phase 2 randomized trial","volume":"31","author":"Skinner","year":"2025","journal-title":"Nat. Med."},{"key":"10.1016\/j.pt.2026.08.002_bb0180","doi-asserted-by":"crossref","first-page":"733","DOI":"10.1016\/j.immuni.2020.08.014","article-title":"A potent anti-malarial human monoclonal antibody targets circumsporozoite protein minor repeats and neutralizes sporozoites in the liver","volume":"53","author":"Wang","year":"2020","journal-title":"Immunity"},{"key":"10.1016\/j.pt.2026.08.002_bb0185","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1056\/NEJMoa2203067","article-title":"Low-dose subcutaneous or intravenous monoclonal antibody to prevent malaria","volume":"387","author":"Wu","year":"2022","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.pt.2026.08.002_bb0190","doi-asserted-by":"crossref","first-page":"1549","DOI":"10.1056\/NEJMoa2312775","article-title":"Subcutaneous administration of a monoclonal antibody to prevent malaria","volume":"390","author":"Kayentao","year":"2024","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.pt.2026.08.002_bb0195","doi-asserted-by":"crossref","first-page":"1614","DOI":"10.1016\/S0140-6736(26)00258-8","article-title":"Safety and efficacy of the monoclonal antibody L9LS for malaria prevention in children exposed to perennial malaria transmission in Kenya: a randomised, double-blind, placebo-controlled, phase 2 trial","volume":"407","author":"Steinhardt","year":"2026","journal-title":"Lancet"},{"key":"10.1016\/j.pt.2026.08.002_bb0200","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1038\/s41591-023-02659-z","article-title":"A candidate antibody drug for prevention of malaria","volume":"30","author":"Williams","year":"2024","journal-title":"Nat. Med."},{"key":"10.1016\/j.pt.2026.08.002_bb0205","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1016\/S1473-3099(25)00481-5","article-title":"Human monoclonal antibody MAM01 for protection against malaria in adults in the USA: a first-in-human, phase 1, dose-escalation, double-blind, placebo-controlled, adaptive trial","volume":"26","author":"Lyke","year":"2026","journal-title":"Lancet Infect. Dis."},{"key":"10.1016\/j.pt.2026.08.002_bb0210","doi-asserted-by":"crossref","first-page":"442","DOI":"10.1038\/s41586-025-09685-6","article-title":"Gene-drive-capable mosquitoes suppress patient-derived malaria in Tanzania","volume":"649","author":"Habtewold","year":"2026","journal-title":"Nature"},{"key":"10.1016\/j.pt.2026.08.002_bb0215","doi-asserted-by":"crossref","DOI":"10.1016\/j.ebiom.2020.103203","article-title":"Pharmacokinetics and predicted neutralisation coverage of VRC01 in HIV-uninfected participants of the Antibody Mediated Prevention (AMP) trials","volume":"64","author":"Huang","year":"2021","journal-title":"EBioMedicine"},{"key":"10.1016\/j.pt.2026.08.002_bb0220","doi-asserted-by":"crossref","first-page":"578","DOI":"10.1016\/S1473-3099(22)00793-9","article-title":"Low-dose intravenous and subcutaneous CIS43LS monoclonal antibody for protection against malaria (VRC 612 Part C): a phase 1, adaptive trial","volume":"23","author":"Lyke","year":"2023","journal-title":"Lancet Infect. Dis."},{"key":"10.1016\/j.pt.2026.08.002_bb0225","doi-asserted-by":"crossref","first-page":"e452","DOI":"10.1016\/S2352-3018(25)00356-X","article-title":"Safety, pharmacokinetics, and neutralisation activity of PGDM1400LS, VRC07-523LS, and PGT121.414.LS infused intravenously or subcutaneously (HVTN 140\/HPTN 101 part B): a phase 1, randomised trial","volume":"13","author":"Mahomed","year":"2026","journal-title":"Lancet HIV"},{"key":"10.1016\/j.pt.2026.08.002_bb0230","doi-asserted-by":"crossref","first-page":"2135","DOI":"10.1093\/jac\/dkaf181","article-title":"Population pharmacokinetics of weight-based compared with fixed dosing of CAP256V2LS, a broadly neutralizing antibody for HIV prevention in women","volume":"80","author":"Mahomed","year":"2025","journal-title":"J. Antimicrob. Chemother."},{"key":"10.1016\/j.pt.2026.08.002_bb0235","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pmed.1004329","article-title":"Safety and pharmacokinetics of VRC07-523LS administered via different routes and doses (HVTN 127\/HPTN 087): a Phase I randomized clinical trial","volume":"21","author":"Walsh","year":"2024","journal-title":"PLoS Med."},{"key":"10.1016\/j.pt.2026.08.002_bb0240","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1208\/s12248-025-01179-7","article-title":"Investigation of monoclonal antibody pharmacokinetics in pediatric population and characterization using a platform PBPK model","volume":"28","author":"Kumar","year":"2026","journal-title":"AAPS J."},{"key":"10.1016\/j.pt.2026.08.002_bb0245","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1007\/s40272-020-00382-7","article-title":"Pharmacokinetics and clinical pharmacology of monoclonal antibodies in pediatric patients","volume":"22","author":"Temrikar","year":"2020","journal-title":"Paediatr. Drugs"},{"key":"10.1016\/j.pt.2026.08.002_bb0250","doi-asserted-by":"crossref","DOI":"10.1093\/jpids\/piaf002","article-title":"Safety, tolerability, and pharmacokinetics of long-acting broadly neutralizing HIV-1 monoclonal antibody VRC07-523LS in newborn infants exposed to HIV-1","volume":"14","author":"Cunningham","year":"2025","journal-title":"J. Pediatric Infect. Dis. Soc."},{"key":"10.1016\/j.pt.2026.08.002_bb0255","doi-asserted-by":"crossref","DOI":"10.1093\/jac\/dkaf449","article-title":"Model-based assessment of VRC07-523LS dosing in infants through population pharmacokinetic \u2013 pharmacodynamic modelling in adults and infants","volume":"81","author":"Huynh","year":"2026","journal-title":"J. Antimicrob. Chemother."},{"key":"10.1016\/j.pt.2026.08.002_bb0260","doi-asserted-by":"crossref","first-page":"1596","DOI":"10.1016\/S1473-3099(22)00428-5","article-title":"Safety, tolerability, and Plasmodium falciparum transmission-reducing activity of monoclonal antibody TB31F: a single-centre, open-label, first-in-human, dose-escalation, phase 1 trial in healthy malaria-naive adults","volume":"22","author":"van der Boor","year":"2022","journal-title":"Lancet Infect. Dis."},{"key":"10.1016\/j.pt.2026.08.002_bb0265","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1080\/19420862.2015.1008353","article-title":"The neonatal Fc receptor (FcRn) binds independently to both sites of the IgG homodimer with identical affinity","volume":"7","author":"Abdiche","year":"2015","journal-title":"MAbs"},{"key":"10.1016\/j.pt.2026.08.002_bb0270","doi-asserted-by":"crossref","first-page":"6866","DOI":"10.1038\/ncomms7866","article-title":"Structural basis for binding of human IgG1 to its high-affinity human receptor Fc\u03b3RI","volume":"6","author":"Kiyoshi","year":"2015","journal-title":"Nat. Commun."},{"key":"10.1016\/j.pt.2026.08.002_bb0275","doi-asserted-by":"crossref","first-page":"44898","DOI":"10.1074\/jbc.M106819200","article-title":"The human low affinity Fcgamma receptors IIa, IIb, and III bind IgG with fast kinetics and distinct thermodynamic properties","volume":"276","author":"Maenaka","year":"2001","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.pt.2026.08.002_bb0280","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1038\/nri.2017.106","article-title":"Beyond binding: antibody effector functions in infectious diseases","volume":"18","author":"Lu","year":"2018","journal-title":"Nat. Rev. Immunol."},{"key":"10.1016\/j.pt.2026.08.002_bb0285","doi-asserted-by":"crossref","first-page":"739","DOI":"10.1146\/annurev.immunol.18.1.739","article-title":"Multiple roles for the major histocompatibility complex class I- related receptor FcRn","volume":"18","author":"Ghetie","year":"2000","journal-title":"Annu. Rev. Immunol."},{"key":"10.1016\/j.pt.2026.08.002_bb0290","doi-asserted-by":"crossref","first-page":"24396","DOI":"10.1016\/S0021-9258(19)51097-3","article-title":"Binding of monomeric immunoglobulin G triggers Fc gamma RI-mediated endocytosis","volume":"269","author":"Harrison","year":"1994","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.pt.2026.08.002_bb0295","doi-asserted-by":"crossref","DOI":"10.1038\/s41467-025-66245-2","article-title":"Inflammation impairs post-hospital discharge growth among children hospitalised with acute illness in sub-Saharan Africa and south Asia","volume":"16","author":"Njunge","year":"2025","journal-title":"Nat. Commun."},{"key":"10.1016\/j.pt.2026.08.002_bb0300","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1038\/s43856-026-01482-0","article-title":"Early-life immunological and microbial differences between East African and North European children","volume":"6","author":"Nurminen","year":"2026","journal-title":"Commun. Med. (Lond.)"},{"key":"10.1016\/j.pt.2026.08.002_bb0305","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1111\/j.1365-2567.2006.02408.x","article-title":"A variable number of tandem repeats polymorphism influences the transcriptional activity of the neonatal Fc receptor alpha-chain promoter","volume":"119","author":"Sachs","year":"2006","journal-title":"Immunology"},{"key":"10.1016\/j.pt.2026.08.002_bb0310","doi-asserted-by":"crossref","first-page":"5512","DOI":"10.1073\/pnas.93.11.5512","article-title":"The protection receptor for IgG catabolism is the beta2-microglobulin-containing neonatal intestinal transport receptor","volume":"93","author":"Junghans","year":"1996","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.pt.2026.08.002_bb0315","doi-asserted-by":"crossref","first-page":"592","DOI":"10.1038\/257592a0","article-title":"Evidence for a malaria mitogen in human malaria","volume":"257","author":"Greenwood","year":"1975","journal-title":"Nature"},{"key":"10.1016\/j.pt.2026.08.002_bb0320","doi-asserted-by":"crossref","first-page":"476","DOI":"10.4065\/76.5.476","article-title":"Retrospective cohort study of 148 patients with polyclonal gammopathy","volume":"76","author":"Dispenzieri","year":"2001","journal-title":"Mayo Clin. Proc."},{"key":"10.1016\/j.pt.2026.08.002_bb0325","doi-asserted-by":"crossref","first-page":"1455","DOI":"10.1080\/17512433.2021.2028619","article-title":"Recent advances in clearance monitoring of monoclonal antibodies in patients with inflammatory bowel diseases","volume":"14","author":"Kantasiripitak","year":"2021","journal-title":"Expert. Rev. Clin. Pharmacol."},{"key":"10.1016\/j.pt.2026.08.002_bb0330","doi-asserted-by":"crossref","DOI":"10.1542\/peds.2024-066508","article-title":"Safety and pharmacokinetics of nirsevimab in immunocompromised children","volume":"154","author":"Domachowske","year":"2024","journal-title":"Pediatrics"},{"key":"10.1016\/j.pt.2026.08.002_bb0335","doi-asserted-by":"crossref","first-page":"2045","DOI":"10.1111\/bcp.13996","article-title":"Evaluation of covariate effects on pharmacokinetics of monoclonal antibodies in oncology","volume":"85","author":"Bajaj","year":"2019","journal-title":"Br. J. Clin. Pharmacol."},{"key":"10.1016\/j.pt.2026.08.002_bb0340","doi-asserted-by":"crossref","first-page":"909","DOI":"10.1016\/j.clnu.2024.02.018","article-title":"The clinical significance of hypoalbuminaemia","volume":"43","author":"Allison","year":"2024","journal-title":"Clin. Nutr."},{"key":"10.1016\/j.pt.2026.08.002_bb0345","doi-asserted-by":"crossref","first-page":"S58","DOI":"10.1002\/jcph.1053","article-title":"Innovative study designs optimizing clinical pharmacology research in infants and children","volume":"58","author":"Balevic","year":"2018","journal-title":"J. Clin. Pharmacol."},{"key":"10.1016\/j.pt.2026.08.002_bb0350","doi-asserted-by":"crossref","first-page":"997","DOI":"10.1080\/17576180.2025.2546782","article-title":"How microsampling is impacting pharmacokinetic and toxicokinetic studies: volumetric absorptive microsampling (VAMS)","volume":"17","author":"Protti","year":"2025","journal-title":"Bioanalysis"},{"key":"10.1016\/j.pt.2026.08.002_bb0355","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1186\/s12929-025-01190-2","article-title":"Technological advancements in antibody-based therapeutics for treatment of diseases","volume":"32","author":"Lu","year":"2025","journal-title":"J. Biomed. Sci."},{"key":"10.1016\/j.pt.2026.08.002_bb0360","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1111\/nyas.15171","article-title":"Global outlook on affordability of biotherapeutic drugs","volume":"1537","author":"Rathore","year":"2024","journal-title":"Ann. N. Y. Acad. Sci."},{"key":"10.1016\/j.pt.2026.08.002_bb0365","doi-asserted-by":"crossref","DOI":"10.1080\/19420862.2025.2451789","article-title":"Cost and supply considerations for antibody therapeutics","volume":"17","author":"Chen","year":"2025","journal-title":"MAbs"},{"key":"10.1016\/j.pt.2026.08.002_bb0370","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pntd.0007860","article-title":"Reassessing therapeutic antibodies for neglected and tropical diseases","volume":"14","author":"Hooft van Huijsduijnen","year":"2020","journal-title":"PLoS Negl. Trop. Dis."},{"key":"10.1016\/j.pt.2026.08.002_bb0375","series-title":"Innovations for exceptionally low-cost monoclonal antibody (mAb) manufacturing","author":"Gates Foundation","year":"2024"},{"key":"10.1016\/j.pt.2026.08.002_bb0380","doi-asserted-by":"crossref","first-page":"2188","DOI":"10.1016\/S0140-6736(02)09096-7","article-title":"Drug development for neglected diseases: a deficient market and a public-health policy failure","volume":"359","author":"Trouiller","year":"2002","journal-title":"Lancet"},{"key":"10.1016\/j.pt.2026.08.002_bb0385","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1016\/j.jclinepi.2018.01.006","article-title":"A mapping of 115,000 randomized trials revealed a mismatch between research effort and health needs in non-high-income regions","volume":"98","author":"Atal","year":"2018","journal-title":"J. Clin. Epidemiol."}],"container-title":["Trends in Parasitology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1471492226002308?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1471492226002308?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,10,8]],"date-time":"2026-10-08T00:58:06Z","timestamp":1791421086000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1471492226002308"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10]]},"references-count":77,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2026,10]]}},"alternative-id":["S1471492226002308"],"URL":"https:\/\/doi.org\/10.1016\/j.pt.2026.08.002","relation":{},"ISSN":["1471-4922"],"issn-type":[{"value":"1471-4922","type":"print"}],"subject":[],"published":{"date-parts":[[2026,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Equitable access to monoclonal antibodies targeting parasites","name":"articletitle","label":"Article Title"},{"value":"Trends in Parasitology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.pt.2026.08.002","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}]}}